TAG:
executive war college
CEO Describes Characteristics Of the Clinical Lab 2.0 Model
By Joseph Burns | From the Volume XXIV No. 7 – May 15, 2017 Issue
CEO SUMMARY: Moving away from volume-based care will not be easy for clinical labs. After all, high volume sustains labs. But labs seeking to transition away from fee-for-service to value-based care must have a seat at the table where decisions are made, said a lab CEO who is part of Proj…
Are Clinical Labs Prepared for What Is to Come?
By R. Lewis Dark | From the Volume XXIV No. 4 – March 13, 2017 Issue
IT IS TIMELY TO ASK THE QUESTION, “Are the nation’s clinical laboratories prepared to deal with the multiple challenges already visible in the healthcare marketplace today?” What leads me to ask this question is the unexpected number of deals involving the hospital lab outreach programs announ…
LabCorp, Quest, Sonic Do Hospital Lab Deals
By Joseph Burns | From the Volume XXIV No. 4 – March 13, 2017 Issue
CEO SUMMARY: Is the New Year’s spate of deals involving the sales of hospital lab outreach programs and a new joint venture the first tremors of an impending earthquake of similar transactions? In the first 10 weeks of 2017, Laboratory Corporation of America, Quest Diagnostics, and Soni…
Ending ‘Lab Tests as a Commodity’
By R. Lewis Dark | From the Volume XXIV No. 2 – January 30, 2017 Issue
WITH HEALTHCARE POISED TO MAKE FUNDAMENTAL CHANGES in both the delivery of care (think integration, ACOs, medical homes) and how providers are paid (less fee-for-service, more budgeted payment metho…
Lab Innovators Advocate Need for Clinical Lab 2.0
By Robert Michel | From the Volume XXIV No. 2 – January 30, 2017 Issue
CEO SUMMARY: It is generally recognized that the clinical lab industry faces a financial squeeze of unprecedented dimensions. Lab test prices are falling steadily and more major cuts are coming to Medicare Part B fees in just 11 months. At the same time, obtaining favorable coverage and r…
Lab, Emergency Department at Cleveland Clinic Collaborate to Reduce Hemolysis Rates
By Joseph Burns | From the Volume XXIII No. 7 – May 23, 2016 Issue
CEO SUMMARY: Two years ago, the rate of hemolysis in blood drawn in the Cleveland Clinic’s Emergency Department was about nine times higher than the ASCP recommended rate of 2%. With a two-year cooperative agreement and funding from the federal Centers for Disease Control and Prevention…
At Executive War College 2016, Two Big Lab Market Trends
By Robert Michel | From the Volume XXIII No. 6 – May 2, 2016 Issue
CEO SUMMARY: What happens when 100 lab experts interact with an audience of more than 850 lab administrators, pathologists, and IVD executives from across the United States and seven other nations? A consensus of sorts emerges and during this 2016 edition of the Executive War College on L…
Giving Back to the Clinical Lab Profession
By R. Lewis Dark | From the Volume XXIII No. 5 – April 11, 2016 Issue
MANY OF US ARE CONCERNED about how the next generation of clinical lab and anatomic pathology leaders will be trained and prepared to step up and assume responsibility for the clinical excellence and financial performance of their respective lab organizations. To contribute to the training of prom…
Understanding the Future Of Laboratory Medicine
By Robert Michel | From the Volume XXIII No. 4 – March 21, 2016 Issue
CEO SUMMARY: Healthcare’s transformation is now far enough along that most clinical labs and pathology groups are either feeling the financial pain or are excitedly developing ways to deliver more value from lab testing services. On April 26-27, at the 21st annual …
March 21, 2016 Intelligence: Late Breaking Lab News
By Robert Michel | From the Volume XXIII No. 4 – March 21, 2016 Issue
Tougher times in the clinical lab testing market have claimed another lab company. On February 28, Artherotech, Inc., posted a notice on its website stating that it had closed permanently, as of that date. Along with its several hundred employees, Artherotech’s closure caught many…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized